drugset / Trial / NCT02324985

Phase II Study of AP0302 5% Versus a Vehicle Comparator

NCT02324985

Phase 2 Completed 147 enrolled Aponia Laboratories, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the analgesic safety and efficacy of study drug (AP0302) applied topically every 6 hours as compared to a vehicle, in subjects experiencing delayed onset muscle soreness.

Timeline

Start
2015-01
Primary completion
2015-07
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexibuprofen Small molecule 5 % Topical

Indications

No indication recorded.